Get started
Work

Supplementary Figure S1 from Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Year: 2023
Type: supplementary-materials
Abstract: Change from baseline in tumor burden of target lesions at patient level
DOI: 10.1158/1078-0432.22477473.v1
Authors: Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo Fernandez, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Jonathan Cheng, Wendy Snyder, Lillian L. Siu
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361937625
Cites:
Cited by:
Related to: 10